Repromed, 180 Fullarton Road Dulwich, South Australia 5065, Australia.
Department of Obstetrics Gynaecology and Reproductive Medicine, Flinders University, Bedford Park, South Australia 5042, Australia.
Asian J Androl. 2021 Jan-Feb;23(1):16-23. doi: 10.4103/aja.aja_41_20.
Oxidative stress is prevalent among infertile men and is a significant cause of sperm DNA damage. Since sperm DNA damage may reduce embryo quality and increase miscarriage rates, it is possible that untreated sperm oxidative stress may impair in vitro fertilization (IVF) live birth rates. Given that the antioxidant Menevit is reported to reduce sperm DNA damage, it was hypothesized that men's consumption of this supplement may alter IVF outcomes. Therefore, a retrospective cohort study was conducted analyzing outcomes for couples undergoing their first fresh embryo transfer. Men were classified as controls if they were taking no supplements, health conscious controls if taking "general health" supplements, or Menevit users. Men with karyotype abnormalities, or cycles using donated, frozen and surgically extracted sperm were excluded. Among the final study cohort of 657 men, live birth rates were significantly higher in Menevit users than controls (multivariate adjusted odds ratio [OR]: 1.57, 95% confidence interval [CI]: 1.01-2.45, P= 0.046), but not between controls taking no supplements and those using general health supplements, thereby suggesting that potential health conscious behavior in supplement users is unlikely responsible for the superior outcomes in Menevit users. Interestingly, in a post hoc sensitivity analysis, live birth rates among Menevit users were statistically superior to controls for lean men (OR: 2.73, 95% CI: 1.18-6.28; P= 0.019), not their overweight/obese counterparts (OR: 1.29, 95% CI: 0.75-2.22, P = 0.37). The results of this large cohort study therefore support a positive association between men's use of the Menevit antioxidant during IVF treatment and live birth rates, especially in lean individuals.
氧化应激在不孕男性中很常见，是精子 DNA 损伤的一个重要原因。由于精子 DNA 损伤可能降低胚胎质量并增加流产率，因此未经治疗的精子氧化应激可能会降低体外受精 (IVF) 的活产率。由于抗氧化剂 Menevit 据称可降低精子 DNA 损伤，因此假设男性服用该补充剂可能会改变 IVF 结局。因此，进行了一项回顾性队列研究，分析了接受首次新鲜胚胎移植的夫妇的结局。如果男性不服用任何补充剂，则将其归类为对照组；如果服用“一般健康”补充剂，则将其归类为健康对照组；如果服用 Menevit，则将其归类为 Menevit 使用者。排除了具有染色体异常的男性或使用捐赠、冷冻和手术提取精子的周期。在最终的研究队列中，有 657 名男性，Menevit 使用者的活产率明显高于对照组（多变量调整后的优势比 [OR]：1.57，95%置信区间 [CI]：1.01-2.45，P=0.046），但对照组服用无补充剂和服用一般健康补充剂之间没有差异，这表明补充剂使用者潜在的健康意识行为不太可能导致 Menevit 使用者的结局更好。有趣的是，在事后敏感性分析中，Menevit 使用者的活产率在瘦男性中明显优于对照组（OR：2.73，95% CI：1.18-6.28；P=0.019），而在超重/肥胖男性中则没有差异（OR：1.29，95% CI：0.75-2.22，P=0.37）。因此，这项大型队列研究的结果支持男性在 IVF 治疗期间使用 Menevit 抗氧化剂与活产率之间存在正相关，尤其是在瘦个体中。
